Pfizer Pays $35 Million to Settle Rapamune Marketing Violations

Drug Industry Daily
A A
Pfizer will pay $35 million divided among 41 states and the District of Columbia to settle allegations it improperly marketed its immunosuppressant Rapamune for unapproved uses, a year after making a $490.9 million deal with the federal government for similar allegations.

To View This Article:

Login

Subscribe To Drug Industry Daily